Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Kacperczyk-Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K., Sugimoto, H., Shalapour, S., Hong, D. S., Heffernan, T. P., Maitra, A., Kalluri, R. (2026). Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. Nature Communications. https://doi.org/10.1038/s41467-026-75960-3